Staphylococcal Acute Post-Operative PJI Treated With 'DAIR' And Impact Of Rifampin
- Conditions
- Bone and Joint InfectionAntibiotic Resistant Staphylococcus Aureus Infection
- Registration Number
- NCT03750721
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
S. aureus and coagulase-negative staphylococci are the most frequent bacteria responsible for PJI (prosthetic joint infection). The aim of this study is to describe the use of rifampicin.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 79
patients having had acute PJI (i.e. <1 month following the implantation), DAIR with exchange of removal components) due to S. aureus and coagulase-negative staphylococci (2011-2016)
None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method description of the use of rifampicin : rate of use Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) the aim is to determine how the use of rifampin influence the prognosis in staphylococcal acute post-operative prosthetic joint infection treated with DAIR
- Secondary Outcome Measures
Name Time Method rate of failure for treatment using rifampin Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin
rate of adverse event with rifampin Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) Description of adverses events leading to stop the rifampicin
Trial Locations
- Locations (1)
Hospices Civils de Lyon
🇫🇷Lyon, France
Hospices Civils de Lyon🇫🇷Lyon, France